2021
Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan
Gibson JA, Finberg KE, Nalbantoglu I, Cecchini M, Ganzak A, Walther Z, Sklar JL, Eder JP, Goldberg SB. Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan. The Lancet Oncology 2021, 22: 306-307. PMID: 33662283, DOI: 10.1016/s1470-2045(20)30683-5.Peer-Reviewed Case Reports and Technical Notes
2020
Targeted Therapies in Advanced Gastric Cancer
Patel TH, Cecchini M. Targeted Therapies in Advanced Gastric Cancer. Current Treatment Options In Oncology 2020, 21: 70. PMID: 32725377, DOI: 10.1007/s11864-020-00774-4.Peer-Reviewed Original ResearchConceptsGastric cancerMetastatic diseaseClinical trialsVascular endothelial growth factor receptor inhibitorDeath ligand 1 (PD-L1) statusEndothelial growth factor receptor inhibitorImmune checkpoint inhibitor pembrolizumabHuman epidermal growth factor 2Epidermal growth factor 2Growth factor receptor inhibitorsBackbone of therapyCheckpoint inhibitor pembrolizumabCombination immune therapyThird-line settingFirst-line settingSecond-line settingAddition of trastuzumabPD-L1 statusAdvanced gastric cancerMetastatic gastric cancerHER2-positive tumorsSquamous cell carcinomaFuture clinical trialsNumerous clinical trialsStandard of care
2018
Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes
Cecchini M, Walther Z, Sklar JL, Bindra RS, Petrylak DP, Eder JP, Goldberg SB. Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes. The Lancet Oncology 2018, 19: 23-24. PMID: 29304353, DOI: 10.1016/s1470-2045(17)30916-6.Peer-Reviewed Case Reports and Technical Notes